Is ldelalisib covered by medical insurance?

Idelalisib (Idelalisib) is a drug used to treat specific types of lymphoma and leukemia. It is a targeted drug and a type of phospholipase Cδ inhibitor (PI3Kδ inhibitor). Idelalisi interferes with the survival and proliferation of leukemia and lymphoma cells by inhibiting phospholipase Cδ (PI3Kδ), a specific signaling pathway protein.

Idelalis is not currently on the market in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase it through overseas channels. There are only original drugs of iderallis available abroad, mainly from the United States, and the price is as high as about 38,000 yuan.

The drug is approved to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), both diseases involving B cells. CLL is a type of leukemia that usually manifests as abnormal proliferation of mature B cells, whereas SLLIt is also a type of B cell lymphoma, which is similar to CLL in many aspects, but mainly manifests as lymph node enlargement and infiltration of abnormal cells.

In clinical practice, idelalix is usually used as adjuvant therapy in patients with CLL and SLL, especially those who have received other treatments but did not achieve a good enough response or have developed drug resistance. This drug can help control the growth of cancer cells, thereby extending patients' survival and improving their quality of life.

However, it is worth noting that idelalix may also cause some adverse reactions, including respiratory infections, hypertension, diarrhea, skin inflammation, and abnormal liver function. Therefore, before using idelalix, doctors will evaluate a patient's overall health and weigh the potential benefits and risks.

xa0